JAK2 and breast carcinoma: We also observed reduced STAT3 signaling in metastases vs primary breast cancer samples in all four clinical cohorts, which concurs with reported inactivating JAK2 and STAT3 mutations in metastatic/relapse samples that are not observed in primary lesions96,97.